www.ema.europa.eu

Syndicate content
Human medicines: pending European commission decisions and European public assessment reports (EPARs)
URL: http://www.ema.europa.eu
Updated: 1 year 34 weeks ago

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Revision: 27, Authorised

Fri, 08/10/2018 - 18:20
Categories: Category 1

Human medicines European public assessment report (EPAR): Sevelamer carbonate Zentiva, sevelamer carbonate, Revision: 10, Authorised

Fri, 08/10/2018 - 17:30
Categories: Category 1

Human medicines European public assessment report (EPAR): GONAL-f, follitropin alfa, Revision: 22, Authorised

Fri, 08/10/2018 - 17:05
Categories: Category 1

Human medicines European public assessment report (EPAR): Bosulif, bosutinib, Revision: 16, Authorised

Fri, 08/10/2018 - 16:50
Categories: Category 1

Human medicines European public assessment report (EPAR): Exforge HCT, amlodipine besylate / valsartan / hydrochlorothiazide, Revision: 13, Authorised

Fri, 08/10/2018 - 15:50
Categories: Category 1

Human medicines European public assessment report (EPAR): Eylea, aflibercept, Revision: 13, Authorised

Fri, 08/10/2018 - 15:30
Categories: Category 1

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Revision: 2, Authorised

Fri, 08/10/2018 - 14:53
Categories: Category 1

Human medicines European public assessment report (EPAR): Genvoya, elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide, Revision: 16, Authorised

Fri, 08/10/2018 - 13:35
Categories: Category 1

Human medicines European public assessment report (EPAR): Mysimba, naltrexone / bupropion, Revision: 10, Authorised

Fri, 08/10/2018 - 10:36
Categories: Category 1

Human medicines European public assessment report (EPAR): Numient, levodopa / carbidopa, Revision: 3, Authorised

Thu, 08/09/2018 - 17:26
Categories: Category 1

Human medicines European public assessment report (EPAR): Fampyra, fampridine, Revision: 12, Authorised

Thu, 08/09/2018 - 17:13
Categories: Category 1

Human medicines European public assessment report (EPAR): Truxima, rituximab, Revision: 6, Authorised

Thu, 08/09/2018 - 17:02
Categories: Category 1

Human medicines European public assessment report (EPAR): Dynastat, parecoxib, Revision: 26, Authorised

Thu, 08/09/2018 - 15:45
Categories: Category 1

Human medicines European public assessment report (EPAR): Rituzena (previously Tuxella), rituximab, Revision: 5, Authorised

Thu, 08/09/2018 - 15:20
Categories: Category 1

Human medicines European public assessment report (EPAR): Ritemvia, rituximab, Revision: 4, Authorised

Thu, 08/09/2018 - 14:45
Categories: Category 1

Human medicines European public assessment report (EPAR): Zonisamide Mylan, zonisamide, Revision: 2, Authorised

Thu, 08/09/2018 - 13:11
Categories: Category 1

Human medicines European public assessment report (EPAR): ATryn, antithrombin alfa, Revision: 15, Authorised

Thu, 08/09/2018 - 11:27
Categories: Category 1

Human medicines European public assessment report (EPAR): Nityr, nitisinone, Revision: 0, Authorised

Thu, 08/09/2018 - 11:00
Categories: Category 1

Human medicines European public assessment report (EPAR): Aimovig, erenumab, Revision: 0, Authorised

Wed, 08/08/2018 - 19:00
Categories: Category 1

Human medicines European public assessment report (EPAR): Rapamune, sirolimus, Revision: 36, Authorised

Wed, 08/08/2018 - 14:53
Categories: Category 1
  • Profesionalumas.
    Esame savo srities specialistai ir mėgstame savo darbą, todėl darbų kokybę garantuojame.
  • Konkurencingumas.
    Poreikius atitinkantys sprendimai už konkurencingą kainą.
  • Konfidencialumas.
    Vertiname bendradarbiavimą, išlaikome konfidencialumą, siekiame tapti ilgalaikiu partneriu.